Literature DB >> 23709326

MicroRNA-21 promotes the proliferation and inhibits apoptosis in Eca109 via activating ERK1/2/MAPK pathway.

Fengxia Liu1, Shutao Zheng, Tao Liu, Qing Liu, Meng Liang, Xiuling Li, Ilyar Sheyhidin, Xiaomei Lu, Wenya Liu.   

Abstract

The aim of this study was to investigate how miR-21 promotes proliferation and inhibits apoptosis in esophageal squamous cell carcinoma (ESCC). MTT, wound healing assay and cell cycle showed that proliferation and migration of ESCC cell line Eca109 cells were increased in miR-21 mimics group, and decreased in anti-miR-21 Oligonucleotide (AMO) group after transfection into Eca109 cells with miR-21 mimics, AMO and scramble sequence, respectively. Cell apoptosis assay indicated that cell apoptosis can be obviously inhibited by overexpression of miR-21 and promoted by downregulation of miR-21. Meanwhile, western-blot results showed that p-ERK1/2 expression was elevated in miR-21 mimics group, whereas decreased in AMO group. Furthermore, the ERK1/2, a key component of MAPK signaling pathway, was knocked down, and overexpressed successfully using shRNA-ERK1/2 and overexpressing plasmids containing full length cDNA of ERK1/2, respectively. It was observed that shRNA-ERK1/2 can significantly decreased the level of miR-21 expression, while overexpression of ERK1/2 can up-regulate expression of miR-21. As further confirmation, Eca109 cells were treated with gradient concentration of U0126, a kind of MEK inhibitor, and expression of miR-21 was subsequently examined. It was found that U0126 can significantly decreased endogenous expression of miR-21. In parallel, U0126 decreased cell proliferation, migration and increased the apoptosis in Eca109 cells, with the expression of miR-21 being reduced significantly in U0126 group as compared with control groups. Our findings indicated that miR-21 promoted the proliferation, migration and inhibited apoptosis of Eca109 cells through activating ERK1/2/MAPK pathway, and that targeting miR-21 could be a promising therapeutic strategy in ESCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23709326     DOI: 10.1007/s11010-013-1693-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

Review 1.  Esophageal cancer.

Authors:  Peter C Enzinger; Robert J Mayer
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

2.  Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.

Authors:  Mark E Hatley; David M Patrick; Matthew R Garcia; James A Richardson; Rhonda Bassel-Duby; Eva van Rooij; Eric N Olson
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

3.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways.

Authors:  W Qin; P Dong; C Ma; K Mitchelson; T Deng; L Zhang; Y Sun; X Feng; Y Ding; X Lu; J He; H Wen; J Cheng
Journal:  Oncogene       Date:  2011-12-19       Impact factor: 9.867

5.  Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma.

Authors:  Junji Kurashige; Hidenobu Kamohara; Masayuki Watanabe; Youhei Tanaka; Koichi Kinoshita; Seiya Saito; Yukiharu Hiyoshi; Masaaki Iwatsuki; Yoshifumi Baba; Hideo Baba
Journal:  J Surg Oncol       Date:  2012-02-21       Impact factor: 3.454

6.  miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.

Authors:  Qin Zhu; Zhiming Wang; Yu Hu; Jindong Li; Xinying Li; Ledu Zhou; Yun Huang
Journal:  Oncol Rep       Date:  2012-02-09       Impact factor: 3.906

7.  MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2).

Authors:  Seonhoe Kim; Ui Jin Lee; Mi Na Kim; Eun-Ju Lee; Ji Young Kim; Mi Young Lee; Sorim Choung; Young Joo Kim; Young-Chul Choi
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

Review 8.  The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer.

Authors:  R Lambert; P Hainaut
Journal:  Best Pract Res Clin Gastroenterol       Date:  2007       Impact factor: 3.043

9.  Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.

Authors:  Surabhi Dangi-Garimella; Jieun Yun; Eva M Eves; Martin Newman; Stefan J Erkeland; Scott M Hammond; Andy J Minn; Marsha Rich Rosner
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

Review 10.  miR-21: a small multi-faceted RNA.

Authors:  Anna M Krichevsky; Galina Gabriely
Journal:  J Cell Mol Med       Date:  2009-01       Impact factor: 5.310

View more
  19 in total

Review 1.  The role of microRNA in esophageal squamous cell carcinoma.

Authors:  Kazuto Harada; Yoshifumi Baba; Takatsugu Ishimoto; Hironobu Shigaki; Keisuke Kosumi; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  J Gastroenterol       Date:  2016-01-21       Impact factor: 7.527

2.  Suppression of endothelial nitric oxide synthase expression and endothelial cell proliferation by an intronic 27-ntmiRNA and it's a novel link to AP-1.

Authors:  Yumei Li; Limei Yan; Wenyu Zhang; Nan Hu; Wei Chen; Hui Wang; Min Kang; Hesheng Ou
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.

Authors:  Hua Xin; Yu Cao; Ming-Liang Shao; Wei Zhang; Chun-Bin Zhang; Jing-Tao Wang; Li-Chun Liang; Wen-Wu Shao; Ya-Ling Qi; Yue Li; Ze-Yu Zhang; Zhe Yang; Yu-Hong Sun; Peng-Xia Zhang; Lin-Lin Jia; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2018-03-09       Impact factor: 2.370

4.  Aberrant upregulation of miR-21 in placental tissues of macrosomia.

Authors:  H Jiang; W Wu; M Zhang; J Li; Y Peng; T-T Miao; H Zhu; G Xu
Journal:  J Perinatol       Date:  2014-05-01       Impact factor: 2.521

5.  GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways.

Authors:  Naoki Urakawa; Soken Utsunomiya; Mari Nishio; Manabu Shigeoka; Nobuhisa Takase; Noriaki Arai; Yoshihiro Kakeji; Yu-ichiro Koma; Hiroshi Yokozaki
Journal:  Lab Invest       Date:  2015-03-02       Impact factor: 5.662

6.  IL-8 is upregulated in cervical cancer tissues and is associated with the proliferation and migration of HeLa cervical cancer cells.

Authors:  Linlin Jia; Fengying Li; Mingliang Shao; Wei Zhang; Chunbin Zhang; Xiaolian Zhao; Haiyan Luan; Yaling Qi; Pengxia Zhang; Lichun Liang; Xiuyue Jia; Kun Zhang; Yan Lu; Zhe Yang; Xiulin Zhu; Qi Zhang; Jiwei Du; Weiqun Wang
Journal:  Oncol Lett       Date:  2017-11-10       Impact factor: 2.967

7.  MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway.

Authors:  Chen Lv; Yuehan Hao; Guanjun Tu
Journal:  Tumour Biol       Date:  2016-01-16

8.  MicroRNA-21 mediates high phosphate-induced endothelial cell apoptosis.

Authors:  Zhaoyu Li; Szymon Wiernek; Cam Patterson; Huanchen Wang; Guoxian Qi; Xuming Dai
Journal:  Am J Physiol Cell Physiol       Date:  2018-09-26       Impact factor: 4.249

9.  microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway.

Authors:  Xiaofeng Yao; Yahui Wang; Dongya Zhang
Journal:  J Mol Neurosci       Date:  2018-04-26       Impact factor: 3.444

10.  Initiation of esophageal squamous cell carcinoma (ESCC) in a murine 4-nitroquinoline-1-oxide and alcohol carcinogenesis model.

Authors:  Kwame Osei-Sarfo; Alison M Urvalek; Xiao-Han Tang; Theresa Scognamiglio; Lorraine J Gudas
Journal:  Oncotarget       Date:  2015-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.